Celularity Inc
↗Florham Park, New Jersey, USA
Celularity Inc is a clinical-stage biotechnology company leading the next evolution in cellular medicine by delivering off-the-shelf allogeneic placenta-derived cellular therapies. Founded in 2016 by Dr. Robert Hariri, the company harnesses the power of the human placenta—nature's immunotherapy engine—to develop regenerative and cellular medicine solutions for cancer, infectious diseases, and degenerative conditions. The company develops CAR-T cell receptor and CAR-NK products for oncology applications, as well as functional regeneration products for wounds, burns, orthopedic and surgical indications. Celularity operates a fully integrated manufacturing, translational research and biobanking facility and maintains one of the industry's largest intellectual property portfolios with over 800 issued patents.
CLASSIFICATION
SIZE & FINANCIALS
Employees:201-500
Revenue:$54.2M (2024)
Founded:2016
Ownership:public
Status:operating
FUNDING
Stage:Public
Total Raised:$750M+
Investors:Genting Berhad/Dragasac Limited, Philip A. Barach, Celgene, Sorrento Therapeutics, United Therapeutics Corporation, Human Longevity Inc
STOCK
Exchange:NASDAQ
Ticker:CELU
Market Cap:$47.9M
PIPELINE
Stage:Phase 1/2 and Phase 2
Lead Drug Stage:CYNK-001 in Phase 1/2 (GBM, AML); PDA-002 in Phase 2 (DFU/PAD)
Modalities:NK cell therapy (Natural Killer cells), CAR-T cell therapy, CAR-NK cell therapy, Placenta-derived mesenchymal stromal-like cells, Placenta-derived pluripotent stem cells, Advanced biomaterials, Allogeneic cell therapy
Active Trials:3
Trial Phases:Phase 1: 1 | Phase 2: 2
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Celgene Cellular Therapeutics (previously)
Key Partnerships:Genting Berhad/Dragasac Limited: Strategic investor and financing partner; developing Fontaine Vitale facility in Bali, Indonesia ($7.2B market-targeting stem cell facility announced 2024), BlueSphere Bio Inc: Master Services Collaboration Agreement for CDMO manufacturing of cell therapies for AML (2025), DefEYE: Exclusive sublicense and investment in $12M Series Seed round, Imugene: Collaboration to develop combination of oncolytic virus with CD19 CAR-T therapy, Regeneron: Multi-year research collaboration services agreement
COMPETITION
Position:Emerging
Competitors:Fate Therapeutics, Caribou Biosciences, Century Therapeutics, Sana Biotechnology, Wugen, Cytovia Therapeutics, Dragonfly Therapeutics, Nakia Therapeutics +5 more
LEADERSHIP
Key Executives:
Robert J. Hariri, M.D., Ph.D. - Founder, Chairman and Chief Executive Officer
Brad Glover, Ph.D. - Executive Vice President and Chief Operating Officer
John R. Haines - Senior Executive Vice President, General Manager and Chief Administrative Officer
Carlos Ramirez - Senior Vice President, Investor Relations
Scientific Founders:Robert J. Hariri, M.D., Ph.D.
Board Members:Robert J. Hariri, M.D., Ph.D. (Chairman and CEO), Richard J. Berman (Board Member), Geoffrey Shiu Fei Ling, M.D., Ph.D. (Board Member)
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Celularity Inc. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.